Reuters logo
BRIEF-Aerie Pharmaceuticals announces FDA acceptance of NDA submission for Rhopressa
May 15, 2017 / 10:44 AM / 6 months ago

BRIEF-Aerie Pharmaceuticals announces FDA acceptance of NDA submission for Rhopressa

May 15 (Reuters) - Aerie Pharmaceuticals Inc

* Aerie Pharmaceuticals announces fda acceptance of nda submission for Rhopressa(netarsudil ophthalmic solution) 0.02%

* Aerie Pharmaceuticals Inc says receives notification from FDA of PDUFA date for Rhopressa

* Aerie Pharmaceuticals Inc- PDUFA goal date for completion of FDA’s review of Rhopressa NDA is set for february 28, 2018

* Aerie Pharmaceuticals Inc - FDA is currently planning to hold an advisory committe Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below